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Abstract: Meningioma is a heterogenous group of primary brain tumors. The progression or recurrence is rela-
tively very common; however, prognostic factors which may indicate those events are not known. The aim of the
study was to evaluate the presence of mast cells within the low grade and high grade meningiomas. The material
included 70 cases of meningomas (63 G1 grade cases) of adult subjects (range 23–84 years). In paraffin sections
presence of tryptase, a marker of mast cells, was detected by immunohistochemistry in 10 random fields in each
slide under the light microscope. The presence of the peritumoral oedema was estimated by brain computer
tomography. The expression of tryptase was observed in 32% of low grade meningiomas and 86% of high grade
meningiomas. The immunostained cells were observed close to the blood vessels. We conclude that the number
of mast cells might be a significant prognostic factor for the recurrence or bad prognosis of meningiomas. (Folia
Histochemica et Cytobiologica 2012, Vol. 50, No. 4, 542–546)
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Introduction
Meningiomas are relatively common, slowly growing
primary intracranial brain tumors, typically arising
from the arachnoidal cap cell of the meninges. The
etiology is still unclear; however there is a close asso-
ciation with the brain trauma or previous head and
neck radiation. Also female gender commonly pre-
disposes to meningioma development, probably due
to the progesterone action [1]. According to WHO
classification meningiomas are graded as G1 (men-
ingothelial, transitional, secretory, fibrous, psammo-
matous, etc), G2 (atypical, clear cell or chordoid) or
G3 (anaplastic, papillary or rhabdoid). Though this
classification involves the presence of such histologi-
cal features like necrosis, mitotic figures, or nuclear
polymorphism [2], tumors belonging to the same sub-
groups can show quite different biological character-
istics like local invasiveness and growth rate, predis-
position to local recurrence after surgical excision,
predisposition to malignancy, presence of peritumoral
brain edema, etc. All these differences cannot be ex-
plained by known molecular aspects of the meningi-
oma development which mostly correlate with NF2
gene mutation (deletion in 22 pair of chromosom
22q12), resulting in merlin protein inactivation. The
frequency of NF2 mutation is similar both in well-
differentiated and in atypical or anaplastic meningi-
omas, therefore NF2 is a very important factor in the
meningioma development, however, not in tumor
progression [3]. The prognosis in most cases is good
and surgical treatment is curable; however, in some
instances recurrence or even progression into less
differentiated meningioma is observed. Still there is
lack of the prognostic factors, which allow predicting
those cases which might behave more aggressively.
Mast cells (MC) are among agents of known po-
tential for promotion of neoplastic transformation.
They contain mediators that can affect fibroblasts or
other inflammatory cells and secrete various cytok-
ines and other vasoactive/inflammatory substances or
growth factors [5–8]. MC are derived from CD34
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positive hematopoietic precursors cells residing in the
bone marrow. They mature in different tissues de-
pending on microenvironmental conditions and play
an important role in allergic reactions, inflammation
or autoimmunological processes [4]. They can be
found also in the central nervous system where they
encircle endothelial cells and pericytes [2]. Brain mast
cells increase in number during neonatal development
or in association with neuronal injury. It is consid-
ered that mast cells may promote development of
tumors through many pathways. Angiogenesis can be
promoted by the activation of endothelin 1 and 2 and/
/or by activation of different growth factors, like Vas-
cular Endothelial Growth Factor (VEGF), IL-8, Epi-
dermal Growth Factor (EGF), Fibroblast Growth
Factor-2 (FGF-2) and others. High mast cells con-
tent is found in neurofibromas, malignant schwanno-
mas, leiomyosarcomas or in other malignancies. Re-
cently it was found that mast cells activation facili-
tates metastases to the brain as well as progression of
breast or lung cancer. This is due to the activation of
histamine, which through H1 receptor induces tumor
cell proliferation. Moreover, activation of metallopro-
teinases disturbs the normal stroma-epithelium com-
munication and permits tumor invasion [2, 5, 9].
The aim of the study was to determine the pres-
ence of mast cells in the meningiomas of various grades.
Material and methods
We examined specimens of 70 meningiomas surgically re-
moved in the Department of Neurosurgery, Medical Uni-
versity of Bialystok in years 2000–2011. The specimens were
fixed in 10% buffered formalin, and then routinely embed-
ded in paraffin blocks. Slides were stained with hematoxy-
lin and eosin and evaluated by pathologist as meningiomas
G1 (low grade meningiomas) and meningiomas G2 or G3
(high grade meningiomas). We also estimated the presence
of the peritumoral oedema in all examined cases. Immuno-
histochemical reaction was carried out to estimate the pres-
ence of mast cells. Following the deparaffinision and rehy-
dration, epitope retrieval was performed in the EnVision
Flex Target Retrieval Solution (DAKO) in high pH. Endog-
enous peroxidases were blocked by incubating the sections
in methanol and 30% hydrogen peroxydase for 20 minutes.
Next, slides were incubated with a typical mast cells’ mark-
er FLEX Monoclonal Mouse Anti-Human Mast Cell
Tryptase, (clon AA1), Ready-to-Use (Link) in room tem-
perature for 20 minutes, complexes were visualized with
EnVision FLEX, High pH (Link) (DAKO) and with DAB
for 10 minutes.
Appropriate positive and negative controls were per-
formed. Negative controls were performed using a non-im-
munized IgG replacing the primary antibody. We used sec-
tions of skin mastocytosis patient as a positive control.
The slides were then counterstained with hematoxylin and
examined under the light microscope Olympus BX45. Im-
munohistochemical evaluation of tryptase expression was
performed by two independent pathologists. The results were
expressed as the percentage of mast cells with a strong posi-
tive tryptase staining and labeled as follows: negative (–) with
£ 10% of positive cells, positive (+) with 11% to 50% of
positive cells and highly positive (++) with ≥ 51% positive
cells in a set of random 10 fields under 20 × magnification.
Statistical analyses were performed by the use of c2 test
and Pearson’s correlation (Statistica 8,0 software). Values
of p < 0,05 were considered as statistically significant.
Results
Among 70 specimens of meningioma there were
63 meningiomas G1: 33 out of them were estimated
as transitional (Figure 1), 10 as meningothelial, 12 as
fibrous (Figure 2) and 8 as mixed meningioma: most-
ly psammomatous — 5 and secretory — 3. The re-
maining meningiomas were in 5 cases atypical (G2)
and in 2 cases anaplastic (G3) (Figure 3 and 4 re-
spectively). This material originated from 23 male and
47 female patients. Among 7 cases of atypical and
anaplastic meningiomas there was only 1 female pa-
tient and 6 were males. The age of patients in the G1
group (I group — low grade) ranged from 28 to 84
years. In the G2 and G3 group (II group — high grade)
the age ranged from 26 to 43 years.
The expression of tryptase in low and high grade
meningiomas is summarized in Table 1. In the I group
(low grade meningiomas) mast cells were observed
in 20/63 cases (31,8%), however 8/20 cases presented
a strong diffused immunoreaction (Figure 5). It was
of note that all psammomatous, secretory and men-
Figure 1. Low grade meningioma with the infiltration of
the dura matter, but without nuclear polymorphism or high
index of mitotic figures; 100 ×
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ingothelial meningiomas were negative for tryptase,
whereas all 12 fibrous and 8 transitional meningiom-
as were positive for tryptase. Comparing all tryptase-
positive high grade meningiomas we found that by
CT brain examination all were sourrounded by
marked peritumoral edema. The immunostaining was
observed mostly next to blood vessels disseminated
within the tumor.
In the group II (high grade meningiomas) all of
the tumors presented edematous changes in CT and
only 1/7 cases was negative for tryptase. One anaplas-
tic meningioma (Figure 6) presented a strong diffused
immunoreaction, the rest of the high grade meningi-
omas showed focal but disseminated positive immu-
noreaction for tryptase (Figures 7, 8).
Discussion
Although most meningiomas are benign, they have
a broad spectrum of clinical and histological pattern,
especially a high incidence of recurrence, even those
estimated as low grade meningiomas after total exci-
sion. Histopathologically there are many types of
meningiomas, but the most important features are the
Figure 2. Fibrous low grade meningioma with hyalinization
fields (histopathological slide for the Fig. 1); 40 ×
Table 1. Tryptase expression in low and high grade menin-
giomas
Tryptase Negative (+) positive (++) positive
expression
No %  No %  No %
Low grade 43 68,2% 12 19% 8 12,8
(I group)
High grade 1 14,3% 5 71,4% 1 14,3%
(II group)
Figure 4. High grade (anaplastic) meningioma with marked
inflammatory cells infiltration (histopathological slide for
the Fig. 3); 100 ×
Figure 5. Strong diffuse tryptase expresion within menin-
gioma of low grade maliganacy; 40 ×
Figure 3. Atypical (high grade) meningioma with the nuclear
polymorphism. The arrow shows intranuclear inclusions
typical for meningioma (mitotic figures > 4/10 hpf); 400 ×
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number of mitotic figures, the presence of necrosis
and the nuclear polymorphism. However, sometimes
these features are not useful enough to predict the
tumors progression; that is why other prognostic fac-
tors are important to estimate. Some data indicate
that not only genetic alterations but also expression
of growth factors (like VEGF or PDGF) can predict
tumor progression [5, 6]. However, so far there is lack
of the prognostic factors, which may be associated with
the meningioma progression or recurrence. In this
study we estimated the presence of mast cells within
the meningioma of various grades.
We found that in high grade meningiomas the
tryptase expression was very strong and diffused; how-
ever, also in low grade meningiomas we observed the
presence of mast cells especially next to the blood
vessels. It is of note that in slow growing psammoma-
tous and meningothelial meningiomas no tryptase
expression was demonstrated. This may be due to the
suppressive effect of psammoma bodies on tumor
growth or due to the effect of tumor environment in
psammoma formation [10]. There is little data con-
cerning the presence of mast cells in meningiomas.
Moradi et al. [2] observed no correlation between
the count of mast cells and the grade of meningiom-
as, a finding which is in opposition to our results.
On the other hand Theoharides et al. [9] suggested
that inflammation including mast cells accumulat-
ing around the tumor could promote tumor growth.
Also Tirakotai et al. [11] demonstrated a high num-
ber of mast cells in secretory meningiomas and found
a correlation with peritumoral oedema. In our study
we found an association between the presence of
mast cells and brain oedema, especially in high grade
group, however, there was no statistically significant
correlation between both parameters because of low
number of examined cases. Epari et al. [12] and
Tena–Suck et al. [13] observed a significant number
of mast cells and B lymphocytes in chordoid menin-
gioma, in the stroma of connective tissue. Similar to
our results were obtained by Bo et al. [14] who ob-
served a statistically significant association between
the number of macrophages and mast cells and mi-
croscopic features of aggressiveness, i.e. high cellu-
larity as well as the combination of nuclear atypia
and frequent mitotic figures. Also Schober et al. [15]
observed in meningiomas mast cells and microcys-
tic alterations which associated with local vascular
permeability disturbances. Popovic et al. [16] pre-
sented a case of meningioma containing a unusually
high number of mast cells and suggested the rela-
tionship between such subtype of meningioma and
subdural hematoma.
In many types of malignant tumors the number of
infiltrating mast cells was shown to correlate with the
Figure 7. Tryptase expression in high grade meningioma
(atypical) with marked peritumoral edema; 100 ×
Figure 8. Few tryptase positive mast cells within the G1
meningioma with marked brain edema; 200 ×
Figure 6. Strong diffuse tryptase immunoexpression within
high grade (anaplastic) meningioma infiltrating the skull;
40 ×
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clinical features and to represent a significant prog-
nostic factor. That progressive increase in mast cell
number associated with an increasingly poor progno-
sis has been shown during the progression of human
melanoma and oral squamous carcinoma [2, 4].
Mast cells synthesize and store large amounts of
metalloproteinases (MMP-2, MMP-9) and serine-pro-
teinases of two subclasses, i.e. tryptase and chymase.
Given the ability of MMP-2 and MMP-9 to degrade
type IV, V, and VII collagens and fibronectin, the ma-
jor components of the interstitial stroma and suben-
dothelial basement membrane, mast cells may contrib-
ute to the in situ progression of invasive and metastat-
ic solid tumors [6, 9, 17]. Our results suggest that the
number of mast cells in meningioma might be a prog-
nostic factor for bad prognosis and tumors recurrence.
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